Literature DB >> 9664969

Liver transplantation in familial amyloidotic polyneuropathy (FAP). A comparative study of transplanted and non-transplanted patient's survival.

O B Suhr1, Y Ando, G Holmgren, L Wikström, S Friman, G Herlenius, B G Ericzon.   

Abstract

The purpose of the present study was to evaluate the impact of liver transplantation on familial amyloidotic polyneuropathy (FAP met-30) patients' survival. Forty-five FAP patients were involved in the study; 15 non-transplanted FAP patients and 30 liver-transplanted patients. All patients' records were scrutinised for information on disease duration. Preoperative nutritional status was evaluated in all patients. No difference in survival was observed for transplanted patients overall compared to historical controls. However, for cases in good nutritional status, an increased survival can be expected as a significantly increased mortality rate for malnourished patients was observed (P < 0.05). Increased survival has so far not been found for transplanted FAP patients. However, none of the transplanted cases has yet reached the expected survival time for nontransplanted FAP control patients. which is 14 years. A high fatality rate of malnourished patients transplanted late in the course of the disease contributed significantly to the mortality among transplanted patients.

Entities:  

Mesh:

Year:  1998        PMID: 9664969     DOI: 10.1007/s001470050451

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  2 in total

1.  Primary Hepatic Amyloidosis Presenting as Acute-on-Chronic Liver Failure.

Authors:  Madhumita Premkumar; Devaraja Rangegowda; Tanmay Vyas; Anand Kulkarni; Shrruti Grover; Rakhi Mahiwall; Shiv Kumar Sarin
Journal:  ACG Case Rep J       Date:  2017-02-15

Review 2.  Evolving landscape in the management of transthyretin amyloidosis.

Authors:  Philip N Hawkins; Yukio Ando; Angela Dispenzeri; Alejandra Gonzalez-Duarte; David Adams; Ole B Suhr
Journal:  Ann Med       Date:  2015-11-27       Impact factor: 4.709

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.